VNDA — Vanda Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $413.76m
- $157.39m
- $216.11m
Annual income statement for Vanda Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 269 | 254 | 193 | 199 | 216 |
| Cost of Revenue | |||||
| Gross Profit | 243 | 230 | 178 | 187 | 203 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 227 | 248 | 207 | 239 | 367 |
| Operating Profit | 42.2 | 6.33 | -14 | -40.7 | -151 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 42.4 | 11.3 | 6.34 | -22.9 | -139 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 33.2 | 6.28 | 2.51 | -18.9 | -220 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 33.2 | 6.28 | 2.51 | -18.9 | -220 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 33.2 | 6.28 | 2.51 | -18.9 | -220 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.855 | 0.11 | 0.044 | -0.325 | -3.74 |